Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonrotoclax + zanubrutinib + CAR-T cell therapy
- Development stage
- Unknown
- Lead developer
- BeOne Medicines
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is a therapeutic regimen being evaluated in a Phase II clinical trial (IND245) led by the Canadian Cancer Trials Group (CCTG) for the treatment of relapsed or refractory mantle cell lymphoma (MCL). The regimen consists of sonrotoclax (BGB-11417), a potent and selective next-generation BCL-2 inhibitor, and zanubrutinib (Brukinsa), a next-generation Bruton's tyrosine kinase (BTK) inhibitor, administered in conjunction with standard-of-care chimeric antigen receptor (CAR) T-cell therapy. The combination aims to enhance the efficacy of CAR-T cell therapy by utilizing targeted small molecules to inhibit survival signaling pathways (BCL-2 and BTK) in malignant B-cells, potentially overcoming resistance and improving durable response rates in patients who have failed prior therapies.
- Brand names
- Brukinsa
- Other names
- Sonrotoclax plus Zanubrutinib and CAR-T cell therapyCCTG IND245 regimenSonrotoclax + Zanubrutinib + CAR-T
02
Targets
Beyond the preview
Go deeper on sonrotoclax + zanubrutinib + CAR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonrotoclax + zanubrutinib + CAR-T cell therapy.